Improving the Quality of Life of Patients with Ureteral Malignant Obstruction

Benoît Vogt1*, Arnaud Desgrippes1, Philippe Laplaige2, Jean-Michel Boulet2, Patrick Seys2 and François-Noël Desfemmes1

1Department of Urology, Polyclinic of Blois, 1 Rue Robert Debré, 41260 The Chaussée Saint-Victor, France
2Department of Oncology, Polyclinic of Blois, 1 Rue Robert Debré, 41260 The Chaussée Saint-Victor, France

Corresponding author: Benoît Vogt, Department of Urology, Polyclinic of Blois, 1 Rue Robert Debré, 41260 , The Chaussée Saint-Victor, France, Tel: 33663220844; E-mail: message@benoitvogt.fr

Received date: Sep 09, 2014, Accepted date: Nov 02, 2014, Published date: Nov 10, 2014

Copyright: © 2014 Vogt B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Short Communication

In a patient with cancer, the ureter may be obstructed by tumor progression. The urologist implants a double-pigtail stent between the kidney and the bladder when an obstruction of the ureter is found.

International scientific medical studies estimate that 80% of patients complain of different symptoms [1]: incontinence, urinary frequency, urgency, dysuria, hematuria, pelvic and lumbar pain. The symptoms are largely due to bladder irritation caused by the stent and by reflux during bladder voiding (Figure 1).

![Figure 1: Appearance of the double-pigtail stents on X ray and appearance of the inflamed ureteral meatus around the double-pigtail stent [2,3].](image)

This treatment-induced suffering can cause an additional suffering to the cancerous symptoms. Thus, we developed a new ureteral stent.

In our view, the original stent is essential to bypass the obstacle but its presence is unnecessary below the stenosis when the ureter is healthy. Thus, the part of the stent in the bladder is of no use in such conditions and its presence may provoke unwanted secondary effects.

In our innovative stent, named pigtail suture stent, the lower part of the stent is replaced by a 0.3F suture thread. The ureteral meatus intubated by the thread shows no inflammation (Figure 2).

![Figure 2: Appearance of the pigtail suture stent on X ray. No ureteral inflammation is visible in contact with the suture thread.](image)

Subsequently, we have improved tolerance stents by creating a profiled tail but industrial manufacturers could further improve the profile of the tail that is currently manually sculpted (Figure 3).

![Figure 3: Appearance of the manually sculpted tail of the pigtail suture stent (endoscopic view).](image)

We used these stents in more than 40 patients with cancer (Prostate, bladder, uterus, colon, and breast) or post-radiation stenosis. Stent symptoms are increased in case of prior pelvic irradiation. These
diseases often force patients to keep the stent for the rest of their lives. This perspective associated with the stent symptoms, strongly affects the patient’s feeling. We wish to inform the oncology community that this new stent can fortunately improve the patient’s quality of life when a malignant tumor causes ureter obstruction.

References

